Delaying standard combined chemoradiotherapy after surgical resection does not impact survival in newly diagnosed glioblastoma patients.
Fiche publication
Date publication
janvier 2016
Journal
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr NOEL Georges
Tous les auteurs :
Louvel G, Metellus P, Noel G, Peeters S, Guyotat J, Duntze J, Le Reste PJ, Dam Hieu P, Faillot T, Litre F, Desse N, Petit A, Emery E, Voirin J, Peltier J, Caire F, Vignes JR, Barat JL, Langlois O, Menei P, Dumont SN, Zanello M, Dezamis E, Dhermain F, Pallud J,
Lien Pubmed
Résumé
To assess the influence of the time interval between surgical resection and standard combined chemoradiotherapy on survival in newly diagnosed and homogeneously treated (surgical resection plus standard combined chemoradiotherapy) glioblastoma patients; while controlling confounding factors (extent of resection, carmustine wafer implantation, functional status, neurological deficit, and postoperative complications).
Mots clés
Antineoplastic Agents, Alkylating, therapeutic use, Brain Neoplasms, drug therapy, Chemoradiotherapy, Combined Modality Therapy, Disease-Free Survival, Female, Glioblastoma, surgery, Humans, Male, Middle Aged, Proportional Hazards Models, Retrospective Studies, Time
Référence
Radiother Oncol. 2016 Jan;118(1):9-15